title: Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
abstract: Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical course that has guided treatment principles in as much as anti-leukemic therapy is reserved for patients with active disease. This heterogeneity is somewhat dissected by prognostic markers, many of which represent pathogenic mechanisms. Recently, the introduction of highly active targeted agents and maturing data on predictive markers may lead to more individualized therapeutic approaches. In this chapter, we review key prognostic markers, current and emerging therapy, and will attempt to outline a future "where the two may connect".
authors: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bld 10, CRC 3-5140, 10 Center Drive, Bethesda, MD, 20892-1202, USA.
authors: Clare
authors: C
authors: Sun
authors: Adrian
authors: A
authors: Wiestner
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11; D002886:Chromosomes, Human, Pair 17; D006801:Humans; D039441:Integrin alpha4 / Q000235:genetics; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000401:mortality* / Q000628:therapy*; D009154:Mutation; D057285:Precision Medicine; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D058496:Smith-Magenis Syndrome; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D039441:Integrin alpha4; D013792:Thalidomide; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D000077269:Lenalidomide